Journal
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
Volume 14, Issue 1, Pages 19-30Publisher
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2016.0004
Keywords
-
Categories
Funding
- AstraZeneca
- Bayer Healthcare Pharmaceuticals Inc.
- Bristol-Myers Squibb
- Clovis Oncology
- Genentech
- Novartis Oncology
- Otsuka America Pharmaceutical, Inc.
- Seattle Genetics, Inc.
- Takeda Oncology
- Actelion Pharmaceuticals US, Inc.
- Astellas
- Medivation, Inc.
- NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease. Recommendations for disease monitoring, treatment of recurrent disease, and systemic therapy for metastatic castration-recurrent prostate cancer also are included. This article summarizes the NCCN Prostate Cancer Panel's most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-naive disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available